BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 25020105)

  • 1. Utility of a Liquid Formulation of Levo-thyroxine in Differentiated Thyroid Cancer Patients.
    Giusti M; Mortara L; Machello N; Monti E; Pera G; Marenzana M
    Drug Res (Stuttg); 2015 Jun; 65(6):332-6. PubMed ID: 25020105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversible normalisation of serum TSH levels in patients with autoimmune atrophic gastritis who received L-T4 in tablet form after switching to an oral liquid formulation: a case series.
    Fallahi P; Ferrari SM; Ruffilli I; Antonelli A
    BMC Gastroenterol; 2016 Feb; 16():22. PubMed ID: 26965518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IN PATIENTS WITH SUBCLINICAL HYPOTHYROIDISM WHILE IN THERAPY WITH TABLET L-T4, THE LIQUID L-T4 FORMULATION IS MORE EFFECTIVE IN RESTORING EUTHYROIDISM.
    Fallahi P; Ferrari SM; Antonelli A
    Endocr Pract; 2017 Feb; 23(2):170-174. PubMed ID: 27849377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Stability of TSH, and Thyroid Hormones, in Patients Treated With Tablet, or Liquid Levo-Thyroxine.
    Antonelli A; Elia G; Ragusa F; Paparo SR; Cavallini G; Benvenga S; Ferrari SM; Fallahi P
    Front Endocrinol (Lausanne); 2021; 12():633587. PubMed ID: 33790863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of adequacy of levo-thyroxine dosage in patients with differentiated thyroid carcinoma: correlation between morning and afternoon TSH determination.
    Conte L; Monti E; Gay S; Marroni P; Adorno A; Mittica M; Mussap M; Giusti M
    J Endocrinol Invest; 2018 Oct; 41(10):1193-1197. PubMed ID: 29476411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation.
    Barbaro D; Boni G; Meucci G; Simi U; Lapi P; Orsini P; Pasquini C; Piazza F; Caciagli M; Mariani G
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4110-5. PubMed ID: 12970272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levothyroxine suppression of thyroglobulin in patients with differentiated thyroid carcinoma.
    Wang PW; Wang ST; Liu RT; Chien WY; Tung SC; Lu YC; Chen HY; Lee CH
    J Clin Endocrinol Metab; 1999 Dec; 84(12):4549-53. PubMed ID: 10599717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advancements in the treatment of hypothyroidism with L-T4 liquid formulation or soft gel capsule: an update.
    Fallahi P; Ferrari SM; Ruffilli I; Ragusa F; Biricotti M; Materazzi G; Miccoli P; Antonelli A
    Expert Opin Drug Deliv; 2017 May; 14(5):647-655. PubMed ID: 27552635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral L-thyroxine liquid versus tablet in patients with hypothyroidism without malabsorption: a prospective study.
    Fallahi P; Ferrari SM; Antonelli A
    Endocrine; 2016 Jun; 52(3):597-601. PubMed ID: 26721663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Shift from Levothyroxine Tablets to Liquid Formulation at Breakfast Improves Quality of Life of Hypothyroid Patients.
    Guglielmi R; Grimaldi F; Negro R; Frasoldati A; Misischi I; Graziano F; Cipri C; Guastamacchia E; Triggiani V; Papini E
    Endocr Metab Immune Disord Drug Targets; 2018; 18(3):235-240. PubMed ID: 29376496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer.
    Biondi B; Cooper DS
    Thyroid; 2010 Feb; 20(2):135-46. PubMed ID: 20151821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long term therapy with a new liquid L-thyroxine preparation: bioequivalence with L-T4 tablets.
    Carpi A; Toni MG; Maccheroni M; De Gaudio C
    Thyroidology; 1992 Dec; 4(3):115-9. PubMed ID: 1285037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum osteoprotegerin and soluble receptor activator of nuclear factor kappaB ligand levels in patients with a history of differentiated thyroid carcinoma: a case-controlled cohort study.
    Giusti M; Cecoli F; Fazzuoli L; De Franchis V; Ceresola E; Ferone D; Mussap M; Minuto F
    Metabolism; 2007 May; 56(5):699-707. PubMed ID: 17445547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liquid L-thyroxine versus tablet L-thyroxine in patients on L- thyroxine replacement or suppressive therapy: a meta-analysis.
    Laurent I; Tang S; Astère M; Wang KR; Deng S; Xiao L; Li QF
    Endocrine; 2018 Jul; 61(1):28-35. PubMed ID: 29572710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up.
    Molinaro E; Giani C; Agate L; Biagini A; Pieruzzi L; Bianchi F; Brozzi F; Ceccarelli C; Viola D; Piaggi P; Vitti P; Pacini F; Elisei R
    J Clin Endocrinol Metab; 2013 Jul; 98(7):2693-700. PubMed ID: 23626005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liquid liothyronine to obtain target TSH in differentiated thyroid cancer patients.
    Trimboli P; Centanni M; Virili C
    Endocr J; 2016 Jun; 63(6):563-7. PubMed ID: 27000530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TSH Normalization in Bariatric Surgery Patients After the Switch from L-Thyroxine in Tablet to an Oral Liquid Formulation.
    Fallahi P; Ferrari SM; Camastra S; Politti U; Ruffilli I; Vita R; Navarra G; Benvenga S; Antonelli A
    Obes Surg; 2017 Jan; 27(1):78-82. PubMed ID: 27272506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching from the tablet to the powder formulation of levothyroxine corrects severe hypothyroidism in a patient with lactose intolerance.
    Jojima T; Shinzawa T; Ohira E; Sakurai S; Tomaru T; Iijima T; Kogai T; Usui I; Aso Y
    Endocr J; 2022 Aug; 69(8):941-945. PubMed ID: 35249899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Skeletal integrity in men chronically treated with suppressive doses of L-thyroxine.
    Marcocci C; Golia F; Vignali E; Pinchera A
    J Bone Miner Res; 1997 Jan; 12(1):72-7. PubMed ID: 9240728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The administration of L-thyroxine as soft gel capsule or liquid solution.
    Vita R; Fallahi P; Antonelli A; Benvenga S
    Expert Opin Drug Deliv; 2014 Jul; 11(7):1103-11. PubMed ID: 24896369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.